Evidence Hub

Clinical characteristics, antimicrobial susceptibility patterns, and treatment outcomes of nontuberculous mycobacterial diseases in eastern China: a retrospective cohort study (2019-2022)

Wang H, Hua H, Chen Y, Zhan Q, Huang H

Microbiology spectrum, 2026

Abstract

ABSTRACT Nontuberculous mycobacteria (NTM) are opportunistic pathogens, and the global incidence of NTM diseases has been steadily increasing, posing significant public health challenges. This study retrospectively analyzed clinical data from 136 cases of NTM disease diagnosed at the Zhejiang Provincial Tuberculosis Diagnosis and Treatment Center between 2019 and 2022. It was observed that NTM diseases in this region predominantly affected middle-aged and elderly men, with chronic cough being the principal symptom (74.3%). Bronchiectasis (57.4%) and cavities (38.2%) were the main imaging characteristics. The results of species identification demonstrated that Mycobacterium intracellulare (62.5%) was the dominant strain. Antimicrobial susceptibility testing revealed that Mycobacterium avium complex exhibited relatively favorable sensitivity to clarithromycin, amikacin, ethambutol, rifapentine, rifampicin, and moxifloxacin, while the Mycobacterium chelonae/Mycobacterium abscessus complex showed sensitivity only to amikacin (66.7%). In total, 66.2% of patients received anti-NTM therapy. Patients completing ≥6 months of treatment achieved significantly higher efficacy than those with <6 months (81.82% vs 57.14%, P < 0.01). The study highlights that NTM diseases in this region are predominantly caused by M. intracellulare, with characteristic clinical/imaging features aiding diagnosis. Treatment regimens guided by susceptibility testing and maintained for ≥6 months significantly…

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free